Quick answer: A new analysis from SmartAsset ranks California, Massachusetts, Delaware, Washington, and Oregon as America's most innovative states, based on patents issued, R&D spending, and venture capital deal value per capita. The states leading the list share a common thread: Heavy investment in research and development. That same R&D activity is exactly what qualifies companies for federal and state R&D tax credits, which are non-dilutive funding that's often left unclaimed, particularly as new Form 6765 documentation requirements take effect for the 2026 tax year.
Which states ranked as most innovative in 2026?
SmartAsset's America's Most Innovative States study scored all 50 states on three per-capita metrics: Patents issued by the U.S. Patent and Trademark Office, research and development expenditures across businesses, universities, and government agencies, and venture capital deal value. The top 10:
- California
- Massachusetts
- Delaware
- Washington
- Oregon
- Colorado
- Connecticut
- Wyoming
- Minnesota
- Idaho
The study frames its analysis around a point the U.S. Economic Development Administration has made about innovation driving competitiveness and job creation, though the ranking itself is SmartAsset's own composite score, not an EDA report.
Why do six Western states dominate the top 10?
California, Washington, Oregon, Colorado, Wyoming, and Idaho form what the study calls America's "Innovation Belt," which is the largest contiguous cluster of top-10 states. The gap between the top and bottom of the list is stark, with California drawing nearly $5,000 in venture capital per resident and producing 129 patents per 100,000 residents; Mississippi, which ranked 50th, drew just $2 per capita and produced four patents per 100,000 residents.
What's notable is that the states get there differently. Massachusetts leads on R&D spending per capita, while Delaware and Wyoming climb the list on venture capital concentration. To that end, Idaho cracked the top 10 with relatively little VC activity, driven instead by more than $600 million in R&D spending tied to Idaho National Laboratory and established manufacturers like Micron and HP.
In other words, a state doesn't need a Silicon Valley-style startup scene to build an innovation economy. It needs sustained R&D investment.
What does this mean for companies doing R&D work?
If your company is investing in product development, engineering, or applied research in any of these states (or anywhere in the U.S.) there's a strong chance a portion of that spend qualifies for the federal R&D tax credit under IRC Section 41, plus a state-level credit layered on top in states that offer one.
That stacking opportunity matters more in 2026 than it has in years. Two changes are reshaping how companies claim the credit:
- Section 174A, enacted under the One Big Beautiful Bill Act (OBBBA), restores immediate expensing for domestic research and experimental costs. This reverses the five-year amortization requirement that had been in effect since 2022, freeing up cash flow for companies actively investing in R&D.
- Form 6765 Section G, the business-component reporting section of the R&D credit form, becomes mandatory for the 2026 tax year for companies above the relevant QRE and revenue thresholds. That means more detailed, project-level documentation is now required to support a claim, not just recommended.
For CFOs and CTOs in high-R&D states, the combination of restored expensing and stricter documentation standards raises the stakes on getting the claim right the first time. Companies that treat R&D tax credits as a once-a-year filing exercise, rather than a documented, ongoing system, are the ones most likely to leave money on the table or struggle under audit scrutiny.
How do the top 10 states' R&D tax credits compare?
Federal eligibility is only half the picture. Nine of the 10 most innovative states also run their own R&D tax credit programs, though the rates, refundability, and restrictions vary enormously, and two of the six "Innovation Belt" states offer no credit at all.
| Rank | State | Credit? | Rate | Refundable? | Notes |
|---|---|---|---|---|---|
| 1 | California | Yes | 15% (regular) or 3% (Alternative Simplified Credit, elected for 2025+) | No | Temporary $5M annual cap on combined business credits for 2024–2026; unused credit carries forward indefinitely |
| 2 | Massachusetts | Yes | 10% of QREs over base, plus 15% on basic research payments | No, except certified life sciences companies (refund up to 90% of unused balance) | 15-year carryforward; credit can’t reduce liability below the $456 minimum excise tax |
| 3 | Delaware | Yes | 10% of excess QREs (20% for businesses under $20M in receipts), or an ASC-based alternative method | Refundable for approved amounts exceeding tax liability | No statewide cap since 2017; application due September 15 with federal Form 6765 attached |
| 4 | Washington | No | — | — | High-Tech B&O R&D credit expired December 31, 2015; Washington also has no state income tax, so the federal credit carries the full weight |
| 5 | Oregon | Limited | N/A for most industries | Partially, for the semiconductor credit only | General R&D credit expired in 2017; a narrow, semiconductor-only credit runs 2024–2030 |
| 6 | Colorado | Yes, geographically limited | 3% of incremental QREs | No | Only available for research performed inside a designated Enterprise Zone; credit usable at 25% per year over 4 years |
| 7 | Connecticut | Yes | 20% incremental, or a tiered 1%–6% non-incremental credit | Partial cash exchange available (33% standard; 90% for qualifying small biotech companies) | Currently limited to C corporations; legislation to expand eligibility to pass-throughs was under review as of early 2026 |
| 8 | Wyoming | No | — | — | No state income tax and no state R&D credit; federal credit is the only avenue |
| 9 | Minnesota | Yes | 10% on the first $2M of excess QREs, 4% above that | Partially refundable starting 2025 (25% rate for 2026–2027) | No Alternative Simplified Credit option; refund election is irrevocable and made on the original return |
| 10 | Idaho | Yes | 5% of excess QREs | No | 14-year carryforward; startup companies can make an irrevocable election for a lower fixed-base percentage |
How does this connect to non-dilutive funding strategy?
Venture capital, the third metric in the SmartAsset study, is dilutive by nature. Every dollar raised comes at the cost of equity. R&D tax credits are the opposite, as they return cash for work a company is already doing, without giving up ownership. For founders and finance leaders in innovation-dense states where VC competition is fierce (or in R&D-heavy states like Idaho where VC is scarce) the tax credit is often the more dependable, repeatable source of funding.
FAQ
The bottom line
Innovation rankings like this one are really a map of where R&D dollars are being spent, and R&D spend is the raw material of a tax credit claim. Boast has helped more than 2,000 companies across North America secure over $900M in R&D tax credits, with an average claim value of $768,233. Whether your business is based in California's crowded innovation economy or a state without a headline-grabbing VC scene, our team can help you find out what your R&D investment is worth in tax credits, and build the audit-ready documentation now required to defend it.
